These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1302 related articles for article (PubMed ID: 29644491)

  • 1. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
    Wang L; Wang Q; Xu Y; Cui M; Han L
    Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF; Matulonis UA
    Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
    Matulonis UA; Wulf GM; Barry WT; Birrer M; Westin SN; Farooq S; Bell-McGuinn KM; Obermayer E; Whalen C; Spagnoletti T; Luo W; Liu H; Hok RC; Aghajanian C; Solit DB; Mills GB; Taylor BS; Won H; Berger MF; Palakurthi S; Liu J; Cantley LC; Winer E
    Ann Oncol; 2017 Mar; 28(3):512-518. PubMed ID: 27993796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib Keeps Hereditary Breast Tumors in Check.
    Cancer Discov; 2017 Aug; 7(8):OF10. PubMed ID: 28583909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    Foote JR; Secord AA; Liang MI; Ehrisman JA; Cohn DE; Jewell E; Havrilesky LJ
    Gynecol Oncol; 2019 Mar; 152(3):445-451. PubMed ID: 30876487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
    Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
    Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 16. A decade of clinical development of PARP inhibitors in perspective.
    Mateo J; Lord CJ; Serra V; Tutt A; Balmaña J; Castroviejo-Bermejo M; Cruz C; Oaknin A; Kaye SB; de Bono JS
    Ann Oncol; 2019 Sep; 30(9):1437-1447. PubMed ID: 31218365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.